• Omicron KP.2 variant adapted vaccine COMIRNATY is now authorized in Canada for individuals 6 months of age and older. It is expected to be available in Canada in the coming weeks.
• The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage.

KIRKLAND, QC, Sept. 24, 2024 /CNW/ - Pfizer Canada ULC and BioNTech SE (NASDAQ:BNTX, ", BioNTech", ))))) announced today that Health Canada has authorized the KP.2 variant adapted COMIRNATY COVID-19 vaccine for ages 6 months and older. The updated COMIRNATY vaccine targets the Omicron KP.2 variant, one of the most recently circulating SARS-CoV-2 lineages.

The adapted COVID-19 vaccine will be available in Canada as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. For children 6 months through 4 years of age, COMIRNATY is authorized for administration as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course, or as a single dose for those with a history of completion of a COVID-19 primary vaccination course.

The newly formulated vaccine will be available in pharmacies and vaccination centers across the country in the fall. Each province and territory will have its own pathway for accessing the vaccine, and individuals are encouraged to refer to their provincial/territorial authorities for more information.

The COVID-19 Vaccines (COMIRNATY) by Pfizer and BioNTech are based on BioNTech's proprietary mRNA technology and were developed by both companies. BioNTech is the Marketing Authorization Holder for COMIRNATY and its adapted vaccines in the United States, the European Union, the United Kingdom, Canada and other countries, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries.